Krystal Biotech, Inc. Share Price
NASDAQ: KRYS | Large CapKrystal Biotech, Inc. Stock Performance
Open $355.19 | Prev. Close $357.63 | Circuit Range N/A |
Day Range $349.12 - $355.19 | Year Range $136.88 - $382.01 | Volume 6,707 |
Average Traded $350.69 |
Krystal Biotech, Inc. Share Price Today
As of 30 August 2026, Krystal Biotech, Inc.'s share price is $351.70. The stock opened at $355.19, compared to its previous close of $357.63. During today's trading session, Krystal Biotech, Inc.'s share price traded between $349.12 and $355.19, with an average price of $352.15. Over the past 52 weeks, the stock has recorded a high of $382.01 and a low of $136.88. In terms of performance, Krystal Biotech, Inc.'s share price has risen by 27.73% over the last six months and is up 138.08% on a year-on-year basis.
Krystal Biotech, Inc. Share Price Chart
Krystal Biotech, Inc. Stock Fundamentals & Key Indicators
Market Cap $10.18B | PE Ratio (TTM) 49.68 | Dividend Yield N/A |
EPS (TTM) $7.08 | Revenue (TTM) $389.13M | Return On Equity (TTM) 16.80% |
Profit Margin 52.64% | Debt to Equity 0.08 | Quarterly Earnings Growth YoY N/A |
Krystal Biotech, Inc. Quarterly Profit & Loss
All figures in USD
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $322.00 | $357.49 | +4.81% |
Jul 2026 | $369.77 | $341.08 | -8.25% |
Jun 2026 | $306.16 | $371.74 | +20.25% |
May 2026 | $263.03 | $309.14 | +17.80% |
Apr 2026 | $258.50 | $262.42 | +1.79% |
Mar 2026 | $267.50 | $257.81 | -6.37% |
Feb 2026 | $279.99 | $275.35 | -1.38% |
Jan 2026 | $245.06 | $279.19 | +12.87% |
Dec 2025 | $213.98 | $247.35 | +13.87% |
Nov 2025 | $196.15 | $217.22 | +10.23% |
Oct 2025 | $179.13 | $197.06 | +11.57% |
Sep 2025 | $147.75 | $176.62 | +19.56% |
KRYS Share Price FAQs
What is Krystal Biotech, Inc. share price today?
What is the 52 week high and 52 week low of Krystal Biotech, Inc. stock?
What is KRYS's market capitalisation today?
What is KRYS's net income for the last quarter?
What is the 5 year returns of KRYS?
What is the high & low stock price of KRYS today?
Can I buy KRYS shares in India?